Vera Therapeutics CEO sells 18,500 shares
Vera Therapeutics, Inc. president and CEO Marshall Fordyce reported open-market sales of a total of 18,500 shares of Class A common stock on May 12, 2026.
Rhea-AI Filing Summary
Vera Therapeutics, Inc. president and CEO Marshall Fordyce reported open-market sales of a total of 18,500 shares of Class A common stock on May 12, 2026. The shares were sold in two tranches of 4,281 shares at a weighted-average price of $37.0868 and 14,219 shares at a weighted-average price of $36.6396, with actual prices ranging from $35.96 to $37.15. These transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on January 9, 2026. The filing also reports indirect holdings through a trust and a GRAT, which together hold more than 200,000 shares after these transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 18,500 shares
Net Sell
4 txns
Insider
Fordyce Marshall
Role
PRESIDENT AND CEO
Sold
18,500 shs ($680K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 14,219 | $36.6396 | $521K |
| Sale | Class A Common Stock | 4,281 | $37.0868 | $159K |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 216,744 shares (Direct);
Class A Common Stock — 122,949 shares (Indirect, By GRAT);
Class A Common Stock — 99,081 shares (Indirect, By Trust)
Footnotes (3)
- F1. This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F2. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.94, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F3. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.15, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Key Figures
Shares sold (first tranche): 4,281 shares
Price (first tranche): $37.0868 per share
Shares sold (second tranche): 14,219 shares
+4 more
7 metrics
Shares sold (first tranche)
4,281 shares
Open-market sale of Class A common stock on May 12, 2026 at weighted-average $37.0868
Price (first tranche)
$37.0868 per share
Weighted-average sale price for 4,281-share transaction
Shares sold (second tranche)
14,219 shares
Open-market sale of Class A common stock on May 12, 2026 at weighted-average $36.6396
Price (second tranche)
$36.6396 per share
Weighted-average sale price for 14,219-share transaction
Total net shares sold
18,500 shares
Net open-market sales reported across two non-derivative transactions
Trust holdings after transaction
99,081 shares
Indirect Class A common stock ownership by trust after May 12, 2026
GRAT holdings after transaction
122,949 shares
Indirect Class A common stock ownership by GRAT after May 12, 2026
Key Terms
Rule 10b5-1(c), weighted-average price, GRAT, open-market sale
4 terms
Rule 10b5-1(c) regulatory
"a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted-average price financial
"The price reported is a weighted-average price. These shares were sold in multiple transactions"
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
GRAT financial
"total_shares_following_transaction: 122949.0000, direct_or_indirect: I, nature_of_ownership: By GRAT"
open-market sale financial
"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Vera Therapeutics (VERA) report for Marshall Fordyce?
Vera Therapeutics reported that president and CEO Marshall Fordyce sold 18,500 shares of Class A common stock in open-market transactions. The trades occurred on May 12, 2026, and were executed under a pre-arranged Rule 10b5-1 trading plan adopted earlier in January 2026.
Were the Vera Therapeutics (VERA) CEO’s stock sales made under a Rule 10b5-1 plan?
Yes. A footnote explains the sales were made under a written trading plan adopted on January 9, 2026, that meets Rule 10b5-1(c) requirements. Such plans schedule trades in advance, helping separate routine portfolio management from discretionary market-timing decisions.
What type of security did the Vera Therapeutics (VERA) insider transactions involve?
All reported transactions involve Vera Therapeutics Class A common stock as non-derivative securities. The Form 4 does not list any option, warrant, or other derivative exercises in this filing, and the derivative position summary shows no derivative transactions for the reported period.
AI-generated analysis. How Rhea-AI works. Not financial advice.
